Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, has been featured in a NetworkNewsWire editorial titled 'Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers.' The article sheds light on Calidi's pioneering platform that employs engineered viruses to deliver genetic therapies directly to tumors, both primary and metastatic. While the company's initial focus is on oncology, it is also exploring applications in autoimmune disorders, indicating a broader therapeutic potential.
The editorial underscores Calidi Biotherapeutics' significant role in tackling the increasing global cancer burden by developing transformative treatment options. The company's proprietary technology is designed to enhance the immune system's ability to combat cancer, utilizing allogeneic stem cells to carry oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors. This approach aims to improve treatment efficacy and patient safety, offering hope for those with hard-to-treat cancers.
Calidi's innovative strategies, including its clinical-stage off-the-shelf, universal cell-based delivery platforms and preclinical off-the-shelf enveloped virotherapies, are poised to make a substantial impact on the treatment of metastatic disease. The company's work represents a critical advancement in the field of genetic medicines, with the potential to revolutionize cancer treatment and beyond.
For more information on Calidi Biotherapeutics and its groundbreaking research, visit https://www.calidibio.com. Additional updates and news related to CLDI can be found in the company's newsroom at https://ibn.fm/CLDI.
